224 related articles for article (PubMed ID: 28638726)
21. Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation.
Velloso FJ; Campos AR; Sogayar MC; Correa RG
BMC Genomics; 2019 Feb; 20(1):152. PubMed ID: 30791886
[TBL] [Abstract][Full Text] [Related]
22. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).
Adams S; Goldstein LJ; Sparano JA; Demaria S; Badve SS
Oncoimmunology; 2015 Sep; 4(9):e985930. PubMed ID: 26405612
[TBL] [Abstract][Full Text] [Related]
23. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
[No Abstract] [Full Text] [Related]
24. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
Noske A; Möbus V; Weber K; Schmatloch S; Weichert W; Köhne CH; Solbach C; Ingold Heppner B; Steiger K; Müller V; Fasching P; Karn T; van Mackelenbergh M; Marmé F; Schmitt WD; Schem C; Stickeler E; Loibl S; Denkert C
Eur J Cancer; 2019 Jun; 114():76-88. PubMed ID: 31075727
[TBL] [Abstract][Full Text] [Related]
25. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.
Harano K; Wang Y; Lim B; Seitz RS; Morris SW; Bailey DB; Hout DR; Skelton RL; Ring BZ; Masuda H; Rao AUK; Laere SV; Bertucci F; Woodward WA; Reuben JM; Krishnamurthy S; Ueno NT
PLoS One; 2018; 13(10):e0204513. PubMed ID: 30312311
[TBL] [Abstract][Full Text] [Related]
26. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
[TBL] [Abstract][Full Text] [Related]
27. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
28. The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.
Jansson S; Aaltonen K; Bendahl PO; Falck AK; Karlsson M; Pietras K; Rydén L
Breast Cancer Res Treat; 2018 Jun; 169(2):231-241. PubMed ID: 29380207
[TBL] [Abstract][Full Text] [Related]
29. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
30. Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes.
Kim JY; Heo SH; Choi SK; Song IH; Park IA; Kim YA; Park HS; Park SY; Bang WS; Gong G; Lee HJ
Virchows Arch; 2017 Apr; 470(4):381-389. PubMed ID: 28185053
[TBL] [Abstract][Full Text] [Related]
31. Whole-Exome Sequencing Reveals High Mutational Concordance between Primary and Matched Recurrent Triple-Negative Breast Cancers.
Kaur J; Chandrashekar DS; Varga Z; Sobottka B; Janssen E; Gandhi K; Kowalski J; Kiraz U; Varambally S; Aneja R
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761830
[TBL] [Abstract][Full Text] [Related]
32. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
33. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
Narrandes S; Huang S; Murphy L; Xu W
BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
[TBL] [Abstract][Full Text] [Related]
34. Differential roles of Bcl2L12 and its short variant in breast cancer lymph node metastasis.
Chien ST; Yang TF; Yang MC; Hsu CM; Hong YR; Lee TM
Oncol Rep; 2015 Aug; 34(2):961-71. PubMed ID: 26082034
[TBL] [Abstract][Full Text] [Related]
35. Treatment Outcomes and Clinicopathologic Characteristics of Triple-Negative Breast Cancer: A Report from Cancer Institute of Iran.
Mirzania M; Safaee SR; Shahi F; Jahanzad I; Zahedi G; Mehdizadeh R
Int J Hematol Oncol Stem Cell Res; 2017 Jan; 11(1):37-42. PubMed ID: 28286613
[No Abstract] [Full Text] [Related]
36. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
37. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
38. No effect of tumor-infiltrating lymphocytes (TILs) on prognosis in patients with early triple-negative breast cancer: Validation of recommendations by the International TILs Working Group 2014.
Park HS; Heo I; Kim JY; Kim S; Nam S; Park S; Kim SI
J Surg Oncol; 2016 Jul; 114(1):17-21. PubMed ID: 27157771
[TBL] [Abstract][Full Text] [Related]
39. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.
Kannan A; Philley JV; Hertweck KL; Ndetan H; Singh KP; Sivakumar S; Wells RB; Vadlamudi RK; Dasgupta S
Sci Rep; 2019 Aug; 9(1):11632. PubMed ID: 31406142
[TBL] [Abstract][Full Text] [Related]
40. Increased hypermethylation of glutathione S-transferase P1, DNA-binding protein inhibitor, death associated protein kinase and paired box protein-5 genes in triple-negative breast cancer Saudi females.
Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Al-Harbi NO; Hassan ZK; Alsheikh A; Al Theyab AI; Aldelemy ML; Sayed-Ahmed MM
Asian Pac J Cancer Prev; 2015; 16(2):541-9. PubMed ID: 25684485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
